View Older Stories View More Recent Stories

Sep 5, 2025 03:21PM Goldman Sachs Reiterates Neutral Rating on Regenxbio Inc. (RGNX)
Sep 5, 2025 11:03AM Raymond James on Regenxbio Inc. (RGNX): 'we think FDA guidance is strongly supportive of HS D2S6 as a biomarker'
Sep 5, 2025 07:05AM REGENXBIO reports sustained biomarker reduction in MPS II gene therapy trial
Aug 19, 2025 06:48AM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Aug 19, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Aug 18, 2025 05:00PM REGENXBIO receives FDA review extension for MPS II gene therapy
Aug 8, 2025 08:52AM Regenxbio Inc. (RGNX) PT Lowered to $17 at RBC Capital
Aug 7, 2025 11:56AM Raymond James Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
Aug 7, 2025 07:13AM Regenxbio (RGNX) Misses Q2 EPS by 44c
Aug 7, 2025 07:00AM REGENXBIO to start pivotal trial for diabetic retinopathy treatment
Jul 10, 2025 11:55AM REGENXBIO publishes preclinical data on RGX-202 gene therapy construct
Jun 6, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Jun 5, 2025 01:21PM Morgan Stanley on Regenxbio Inc. (RGNX): 'we continue to appreciate RGNX’s diversified mid- to late-stage gene therapy pipeline'
Jun 5, 2025 01:15PM Leerink on Regenxbio Inc. (RGNX): 'the path to accelerated approval is likely clear, valuation is undemanding, and balance sheet robust'
Jun 5, 2025 12:26PM Raymond James Defending Regenxbio Inc. (RGNX): 'we see this as a good entry point'
Jun 5, 2025 12:25PM BofA Securities Defending Regenxbio Inc. (RGNX), Shares Down 15pct
Jun 5, 2025 12:14PM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX) Following DMD data
Jun 5, 2025 07:05AM Regenxbio (RGNX) Reports New Data from Phase I/II Affinity Trial
May 20, 2025 08:05AM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
May 19, 2025 04:05PM Regenxbio (RGNX) Announces Strategic Royalty Monetization Agreement for Up to $250 Million
May 13, 2025 09:24AM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
May 13, 2025 07:07AM Regenxbio (RGNX) Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
May 12, 2025 04:12PM Regenxbio (RGNX) Misses Q1 EPS by 36c; offers guidance
Mar 31, 2025 04:37PM Clear Street Starts Regenxbio Inc. (RGNX) at Buy, PT $50
Mar 19, 2025 03:06PM Baird's Brian Skorney Comments on Regenxbio Inc. (RGNX): 'We also think it's favorable that REGENXBIO is able to learn from Elevidys' faults'
Mar 19, 2025 03:04PM Regenxbio Inc. (RGNX) PT Raised By $2 to $29 at Raymond James, 'Model Tweak for STEER Results', Shares +6pct Today
Mar 19, 2025 09:15AM Regenxbio (RGNX) Reports Positive Biomarker Data From Affinity Duchenne Trial of RGX-202 Gene Therapy
Mar 17, 2025 06:40AM Regenxbio Inc. (RGNX) PT Lowered to $34 at H.C. Wainwright
Mar 14, 2025 09:11AM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Mar 13, 2025 04:13PM Regenxbio (RGNX) Tops Q4 EPS by 12c
Mar 4, 2025 07:31AM Regenxbio (RGNX) Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
Feb 11, 2025 03:58AM Goldman Sachs Downgrades Regenxbio Inc. (RGNX) to Neutral
Feb 6, 2025 04:02PM Raymond James Starts Regenxbio Inc. (RGNX) at Outperform
Jan 15, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Jan 14, 2025 06:09AM Regenxbio (RGNX) and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111
Jan 13, 2025 08:31AM AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program
Dec 6, 2024 07:40PM Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Dec 6, 2024 05:27PM Apollo Global Management (APO) and Workday (WDAY) to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Nov 21, 2024 06:36AM Regenxbio Inc. (RGNX) PT Lowered to $36 at H.C. Wainwright
Nov 18, 2024 02:15PM Raymond James Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
Nov 18, 2024 07:10AM Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data
Nov 15, 2024 03:19AM Morgan Stanley Assumes Regenxbio Inc. (RGNX) at Overweight
Nov 6, 2024 05:00PM Regenxbio (RGNX) Misses Q3 EPS by 5c
Oct 21, 2024 07:06AM Regenxbio (RGNX) Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Oct 10, 2024 08:22AM Raymond James Resumes Regenxbio Inc. (RGNX) at Outperform
Sep 17, 2024 07:07AM Regenxbio (RGNX) Appoints Mitchell Chan as CFO
Sep 5, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Sep 3, 2024 08:05AM Regenxbio (RGNX) Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
Aug 1, 2024 04:41PM Regenxbio (RGNX) Tops Q2 EPS by 24c, provides guidance
Aug 1, 2024 07:03AM Regenxbio (RGNX) Announces New Positive Data From Affinity Duchenne® Trial Of Rgx-202
View More Recent Stories View Older Stories